Search - tctmd.com

Displaying 681 - 700 of 779

Sort: Relevancy | Date

Presentation TCTAP 2013

The Future Is: New Antiplatelet Agents, Selective Platelet Function Testing, and Patient-Specific DAPT Duration

Presenter: Matthew J. Price

April 24, 2013

Presentation TCTAP 2013

Counterpoint: The Incremental Benefit Is Small and the Cost-Disadvantages of New DAPT Approaches Are Prohibitive

Presenter: Adnan Kastrati

April 24, 2013

News Daily News

Rivaroxaban Added to Dual Antiplatelet Therapy Cuts Stent Thrombosis in ACS Patients

Caitlin E. Cox

April 19, 2013

News Daily News

Rivaroxaban + Terapia Antiplaquetaria Doble Reducen la Trombosis del Stent en Pacientes víctimas de un SCA

Caitlin E. Cox

April 19, 2013

Presentation

Decision Dilemmas in Adjunctive Pharmacology Choices in PCI Patients

Presenter: Roxana Mehran

April 15, 2013

News Daily News

Registro Danés: El Dabigatran es Seguro y Eficaz en el Mundo Real

Caitlin E. Cox

April 05, 2013

News Daily News

Danish Registry: Dabigatran Safe, Effective in Real-World Use

Caitlin E. Cox

April 05, 2013

Presentation

Nuisance Bleeding with Prolonged Dual Antiplatelet Therapy After AMI and Its Impact on Health Status

Presenter: A. P. Amin

March 26, 2013

Presentation

ADAPT-DES One-Year Results: A Large-Scale, Multicenter, Prospective, Observational Study of the Impact of Clopidogrel and Aspirin Hyporesponsiveness on Patient Outcomes

Presenter: Gregg W. Stone

March 26, 2013

News Conference News ACC 2013

Aspirin Alone Just as Good as Dual Antiplatelet Therapy Beyond 12 Months

Jason Kahn

March 11, 2013

News Conference News ACC 2013

Rosuvastatin Helps Stave Off Contrast Nephropathy in NSTE-ACS Patients

L.A. McKeown

March 09, 2013

Presentation PCI Outcomes 2013

DAPT + Oral Anticoagulation: Indications and Risk Amelioration

Presenter: C. Michael Gibson

March 07, 2013

News Daily News

Atorvastatin Boosts Clopidogrel Efficacy in Patients with High Platelet Reactivity

February 25, 2013

News Daily News

La Duración Ideal de la Terapia Antiplaquetaria Doble podría Depender del Tipo de Stent

Jason Kahn

January 22, 2013

News Daily News

Ideal Duration of Dual Antiplatelet Therapy May Depend on Stent Type

Jason Kahn

January 22, 2013

Presentation

Should Duration of Dual Antiplatelet Therapy Depend on the Type and/or Potency of Implanted Stent?

Presenter: Marco Valgimigli

January 16, 2013

News Daily News

Una Dosis Alta de Aspirina tras una PCI Primaria aumenta las Hemorragias No observandose Beneficio Isquémico alguno

L.A. McKeown

December 19, 2012

News Daily News

High-Dose Aspirin After Primary PCI Increases Bleeding with No Ischemic Benefit

L.A. McKeown

December 19, 2012

Presentation

Safety and Efficacy of High- vs. Low-Dose Aspirin After Primary PCI in STEMI

Presenter: J. Yu

December 17, 2012

News Daily News

Risk Factor Control Linked to Better Outcomes After Peripheral Intervention

Caitlin E. Cox

December 16, 2012

Advertisement

The Future Is: New Antiplatelet Agents, Selective Platelet Function Testing, and Patient-Specific DAPT Duration

Counterpoint: The Incremental Benefit Is Small and the Cost-Disadvantages of New DAPT Approaches Are Prohibitive

Rivaroxaban Added to Dual Antiplatelet Therapy Cuts Stent Thrombosis in ACS Patients

Rivaroxaban + Terapia Antiplaquetaria Doble Reducen la Trombosis del Stent en Pacientes víctimas de un SCA

Decision Dilemmas in Adjunctive Pharmacology Choices in PCI Patients

Registro Danés: El Dabigatran es Seguro y Eficaz en el Mundo Real

Danish Registry: Dabigatran Safe, Effective in Real-World Use

Nuisance Bleeding with Prolonged Dual Antiplatelet Therapy After AMI and Its Impact on Health Status

ADAPT-DES One-Year Results: A Large-Scale, Multicenter, Prospective, Observational Study of the Impact of Clopidogrel and Aspirin Hyporesponsiveness on Patient Outcomes

Aspirin Alone Just as Good as Dual Antiplatelet Therapy Beyond 12 Months

Rosuvastatin Helps Stave Off Contrast Nephropathy in NSTE-ACS Patients

DAPT + Oral Anticoagulation: Indications and Risk Amelioration

Atorvastatin Boosts Clopidogrel Efficacy in Patients with High Platelet Reactivity

La Duración Ideal de la Terapia Antiplaquetaria Doble podría Depender del Tipo de Stent

Ideal Duration of Dual Antiplatelet Therapy May Depend on Stent Type

Should Duration of Dual Antiplatelet Therapy Depend on the Type and/or Potency of Implanted Stent?

Una Dosis Alta de Aspirina tras una PCI Primaria aumenta las Hemorragias No observandose Beneficio Isquémico alguno

High-Dose Aspirin After Primary PCI Increases Bleeding with No Ischemic Benefit

Safety and Efficacy of High- vs. Low-Dose Aspirin After Primary PCI in STEMI

Risk Factor Control Linked to Better Outcomes After Peripheral Intervention

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content